AR-V7-a novel predictive and prognostic Biomarker Therapy Individualization in castration-resistant Prostate Cancer

被引：0
|
作者：
Oing, C. [1 ]
von Amsberg, G. [1 ]
Bokemeyer, C. [1 ]
机构：
[1] Univ Klinikum Hamburg Eppendorf, Med Klin Onkol Hamatol & Stammzelltransplantat Se, D-20246 Hamburg, Germany
来源：
ONKOLOGE | 2015年 / 21卷 / 09期
关键词：
ABIRATERONE ACETATE; ENZALUTAMIDE; DOCETAXEL;
D O I：
10.1007/s00761-015-3019-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：846 / 847
页数：2
相关论文
共 50 条
  • [21] A novel AR splice variant identified in circulating tumor cells from castration-resistant prostate cancer patient blood as a potentially prognostic biomarker
    Kang, Zhigang
    Yu, Yunkai
    Cao, Liang
    Meltzer, Paul S.
    Zhu, Yuelin
    Shah, Avan
    Gulley, James
    Duht, William
    Madan, Ravi
    Bhagat, Ali
    Zhao, Kyra
    CANCER RESEARCH, 2014, 74 (19)
  • [22] Pathophysiology and therapy of castration-resistant prostate cancer
    Merseburger, A. S.
    Kuczyk, M. A.
    Wolff, J. M.
    UROLOGE, 2013, 52 (02): : 219 - 225
  • [23] Satraplatin for the therapy of castration-resistant prostate cancer
    Sonpavde, Guru
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2009, 5 (07) : 931 - 940
  • [24] Development of AR-V7 as a putative treatment selection marker for metastatic castration-resistant prostate cancer
    Luo, Jun
    ASIAN JOURNAL OF ANDROLOGY, 2016, 18 (04) : 580 - 585
  • [25] Serum γ-Glutamyltransferase as a Prognostic Biomarker in Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide
    Takemura, Kosuke
    Ito, Masaya
    Nakanishi, Yasukazu
    Kataoka, Madoka
    Sakamoto, Kazumasa
    Suzuki, Hiroaki
    Tobisu, Ken-ichi
    Koga, Fumitaka
    ANTICANCER RESEARCH, 2019, 39 (10) : 5773 - 5780
  • [26] HSK38008: An oral AR-V7 degrader for metastatic castration-resistant prostate cancer
    Wang, Ju
    Qian, Meilin
    Yan, Pangke
    Li, Linli
    Zhang, Chen
    Yu, Yan
    Tao, Lihua
    Tang, Pingming
    Liao, Yuting
    Chen, Xiaogang
    Cheng, Xinfan
    Xu, Jinxiong
    Wan, Xuemei
    Deng, Luchan
    Dong, Hongjiao
    Zhang, Haixian
    He, Maotao
    CANCER RESEARCH, 2023, 83 (08)
  • [27] Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13
    Chen, Zhong
    Wu, Dayong
    Thomas-Ahner, Jennifer M.
    Lu, Changxue
    Zhao, Pei
    Zhang, Qingfu
    Geraghty, Connor
    Yan, Pearlly S.
    Hankey, William
    Sunkel, Benjamin
    Cheng, Xiaolong
    Antonarakis, Emmanuel S.
    Wang, Qi-En
    Liu, Zhihua
    Huang, Tim H-M
    Jin, Victor X.
    Clinton, Steven K.
    Luo, Jun
    Huang, Jiaoti
    Wang, Qianben
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (26) : 6810 - 6815
  • [28] Novel treatments for castration-resistant prostate cancer
    Sternberg, Cora N.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S195 - S199
  • [29] Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?
    Leibrand, Crystal R.
    Price, Douglas K.
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2016, 17 (05) : 467 - 469
  • [30] Bumped kinase inhibitors: A novel therapy for castration-resistant prostate cancer
    Sprenger, Cynthia C.
    Plymate, Stephen
    Maly, Dustin
    Van Voorhis, Wesley
    Ojo, Kayode K.
    CANCER RESEARCH, 2016, 76
12345